Construction begins on Rentschler Biopharma’s new facility in Massachusetts, US

WCN Editorial Team 13 Aug 2021 NORTH AMERICA BUILDINGS

Rentschler Biopharma has commenced construction on its new production site, adjacent to its existing site in Milford, Massachusetts, the US.

The new 22,000ft2 facility, named Rentschler Biopharma Manufacturing Center US (RBMC US), will house four new 2,000l single-use bioreactors.

It will expand the company’s cGMP manufacturing capacity and accelerate the clinical and commercial supply of biopharmaceuticals.

The new facility’s design features upstream ballroom processing sized for production flexibility and can also accommodate future adaptations to increase capacity.

The company stated that the site will also include expanded quality control (QC), development, and warehousing capabilities.

RBMC US will provide digital and analytical services that include advanced analytics yield optimisation, augmented/virtual reality-enabled operations and no-touch batch releases.

Rentschler Biopharma CEO Frank Mathias said: “With Rentschler Biopharma’s contribution to the production of mRNA vaccines to beat the COVID-19 virus, we have seen firsthand how important it is to have highly adaptable capacity and to have the experience and expertise needed to produce new therapeutic modalities, fast.

“The U.S. expansion we have kicked off at the groundbreaking is part of our ongoing plan to strategically grow our business as we support our clients in developing and manufacturing even highly complex molecules.

“We must always be ready to meet the ongoing and ever-changing challenges of reliably bringing new treatments to patients.”

Slated to commence operations in late 2023, the new facility will add space for manufacturing and enables the US operations to centralise support services to produce essential biopharmaceuticals.

The company said that its existing Milford facility has been changed from a single-product commercial facility to multiple-products facility with up to 500l bioreactor.


Rentschler Biopharma breaks ground on new production facility in Massachusetts. Credit: Rentschler Biopharma SE.

With 11 websites and newsletters covering all the key areas within the construction industry, World Construction Industry Network is the leading global construction information resource. READ ABOUT US



World Construction Network | is a product of GlobalData. Copyright © 2022 GlobalData. All rights reserved.